RE: Lateral Flow Test providers24 Oct 2021 10:02
Which test is best has now come down to cost. I expect the general public will choose the cheapest. The PCR revenue was welcome but I think will now take a back seat and our future is with the 'core' products.
I can't say I'm to disappointed as I've posted before that I prefer us to be engaged in relatively niche products where we have a clear, and sometimes a unique advantage, rather than competing with a whole range of other companies. NIPT was the original attraction for me and the merger with Elucigene and Genomic services were examples of the intention to develop niche products into new markets. To YGENs credit the covid-19 distraction was well handled - maybe a little slow to start with but an excellent finished product. I just feel we're getting back to our major real business. Onwards and upwards!